Patients with multiple sclerosis acquire disability either through relapse-associated deterioration (RAW) or relapse-independent progression (PIRA). One study now addressed the questions of how early progression begins in the course of the disease and to what extent multiple sclerosis therapies can delay the increase in disability.
Autoren
- Leoni Burggraf
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Lymphoma
Treatment goal: slow progression, improve quality of life
- PancNEN, PancNET & PancNEC
Neuroendocrine tumors of the pancreas
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Headache treatment
The therapy of migraine
- Sleep disorders in old age